SCHEMBL4896026

SCHEMBL4896026

CCN(c1ccc(Br)cc1)S(=O)(=O)c1ccc(C)c(C(=O)OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
TSHR P16473 1/20 0.49
LMNA P02545 4/20 0.47
ESR1 P03372 2/20 0.47
NPSR1 Q6W5P4 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HDAC8 Q9BY41 3/20 0.43
HDAC3 O15379 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
ATM Q13315 1/20 0.43
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41
GRK2 P25098 1/20 0.41
DNMT1 P26358 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902733 0.89 ESR1 (0.60) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4897517 0.88 ALDH1A1 (0.49) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4906761 0.87 ALDH1A1 (0.48) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4906992 0.87 ESR1 (0.44) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4905482 0.87 NPSR1 (0.51) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4902995 0.86 HCRTR2 (0.47) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4899320 0.85 ALDH1A1 (0.52) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4904034 0.85 LMNA (0.50) ALDH1A1TSHRLMNAESR1NPSR1
SCHEMBL4898279 0.85 MAPT (0.51) ALDH1A1TSHRLMNAESR1SMN1; SMN2
SCHEMBL4903818 0.84 ESR1 (0.52) ALDH1A1LMNAESR1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
EP-1765796-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Inc. (US) 2007-03-28 EP disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
WO-2006003495-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2006-01-12 WO disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD ALDH1A1 2664/4885TSHR 412/4885LMNA 317/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD ALDH1A1 2956/4885TSHR 400/4885LMNA 319/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD ALDH1A1 2956/4885TSHR 400/4885LMNA 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.